Currently, as various regions are vigorously advancing the development of the biopharmaceutical industry, the demand for related talent has also begun to expand significantly. This year alone, numerous regions have launched recruitment initiatives targeting professionals in the biopharmaceutical sector, with some offering annual salaries as high as 3 million yuan. For instance, recently at the Centralized Signing Ceremony of the first batch of key projects for Hainan Free Trade Port in 2022, Haikou announced globally its need for 1,510 talent positions specifically within the biopharmaceutical industry.
Against the backdrop of robust growth in the biopharmaceutical industry, various regions across China are now further accelerating their efforts to promote high-quality development in this sector. It is reported that multiple localities have already successively unveiled their respective plans for developing the biopharmaceutical industry this year.
Recently, the Fujian Provincial Government issued the "Implementation Plan for Accelerating the High-Quality Development of the Biopharmaceutical Industry in Fujian Province" (hereinafter referred to as the "Implementation Plan"), outlining a series of robust and highly operational policy measures aimed at providing substantial support.
The Implementation Plan focuses on six key areas—enhancing industrial technological innovation capabilities, coordinating industrial development strategies, strengthening enterprises as the main drivers of innovation, improving the service system, accelerating the application and promotion of innovative products, and bolstering resource support—to precisely implement targeted measures and drive forward the high-quality development of Fujian's biopharmaceutical industry.
Focusing on six priority sectors—biopharmaceuticals, chemical drugs, traditional Chinese medicine, high-end medical devices, biomanufacturing, and biopharmaceutical services—the plan aims to achieve an annual operating revenue of 120 billion yuan for Fujian's pharmaceutical industry by 2025. It also seeks to cultivate a group of leading enterprises, develop key innovative products, establish robust technology R&D and public service platforms, and foster distinctive industrial clusters.
In addition, the Implementation Plan clearly states that Fujian will focus on building Xiamen into a leading hub for the biopharmaceutical industry, accelerating the strategic deployment of the biopharmaceutical sector within Xiamen Science City, and advancing the construction of the Xiamen National Health Industry International Innovation Park.
On March 28, the "Yunnan Province '14th Five-Year' Plan for Innovative Development of the Biomedical Industry" was released, outlining the goal of achieving "maintaining at least 4% growth while striving for 5%" in the province's biomedical industry revenue by 2025.
According to the objectives, by 2025, Yunnan Province's biopharmaceutical industry is expected to achieve an annual operating revenue of at least 400 billion yuan, with efforts aimed at reaching 500 billion yuan, representing an average annual growth rate of over 10%. Specifically, the biopharmaceutical manufacturing sector will generate an operating revenue exceeding 150 billion yuan, with an average annual growth rate of more than 20%; meanwhile, the added value of the biopharmaceutical industry is projected to reach 120 billion yuan, maintaining an average annual growth rate of over 10%.
Currently, as various regions are vigorously developing the biopharmaceutical industry, the demand for related talent has also begun to expand significantly. This year alone, numerous regions have launched recruitment initiatives targeting professionals in the biopharmaceutical sector, with some offering annual salaries as high as 3 million yuan. For instance, recently at the集中签约会 (Centralized Signing Ceremony) of the first batch of key projects for Hainan Free Trade Port in 2022, Haikou announced globally its need for 1,510 talent positions specifically within the biopharmaceutical industry.
Specifically, Haikou's current recruitment drive seeks 106 positions requiring doctoral or higher qualifications, 130 roles demanding master's degrees or above, and 727 positions calling for bachelor's degrees or higher. Among these, there are 209 R&D roles, 122 senior management positions, 262 posts in inspection and testing, and 21 engineering and technical roles. In terms of annual salaries, high-level talent positions in the biopharmaceutical field offer compensation ranging from 500,000 to 3 million yuan.
On March 30, Chengdu High-Tech Zone also released the first batch of the 2022 Chengdu High-Tech Zone Golden Panda List of High-Caliber Talent Needs, the first batch of postdoctoral recruitment lists, and the construction plan for the Chengdu High-Tech Zone's Online Platform for High-End Talent Services.
Analysts believe that, driven by continuously favorable national policies and the ongoing influx of global biopharmaceutical talent into China, the biopharmaceutical industries across the country are expected to experience rapid growth, thereby propelling the entire sector toward higher-quality development.
Disclaimer: Under no circumstances should the information or opinions expressed in this document be construed as investment advice to anyone.
